TuHURA Biosciences (HURA) Competitors $2.40 -0.11 (-4.20%) As of 01:53 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock HURA vs. ZVRA, PRME, BCYC, EOLS, REPL, CMPS, RGNX, ARCT, CMPX, and ETONShould you be buying TuHURA Biosciences stock or one of its competitors? The main competitors of TuHURA Biosciences include Zevra Therapeutics (ZVRA), Prime Medicine (PRME), Bicycle Therapeutics (BCYC), Evolus (EOLS), Replimune Group (REPL), COMPASS Pathways (CMPS), REGENXBIO (RGNX), Arcturus Therapeutics (ARCT), Compass Therapeutics (CMPX), and Eton Pharmaceuticals (ETON). These companies are all part of the "pharmaceutical products" industry. TuHURA Biosciences vs. Its Competitors Zevra Therapeutics Prime Medicine Bicycle Therapeutics Evolus Replimune Group COMPASS Pathways REGENXBIO Arcturus Therapeutics Compass Therapeutics Eton Pharmaceuticals Zevra Therapeutics (NASDAQ:ZVRA) and TuHURA Biosciences (NASDAQ:HURA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Which has more risk & volatility, ZVRA or HURA? Zevra Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, TuHURA Biosciences has a beta of -0.1, indicating that its stock price is 110% less volatile than the S&P 500. Do analysts recommend ZVRA or HURA? Zevra Therapeutics presently has a consensus target price of $23.71, suggesting a potential upside of 225.08%. TuHURA Biosciences has a consensus target price of $12.67, suggesting a potential upside of 428.88%. Given TuHURA Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe TuHURA Biosciences is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89TuHURA Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 2 Strong Buy rating(s) 3.40 Do institutionals & insiders hold more shares of ZVRA or HURA? 35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 0.6% of TuHURA Biosciences shares are owned by institutional investors. 2.4% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 0.2% of TuHURA Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media favor ZVRA or HURA? In the previous week, Zevra Therapeutics had 3 more articles in the media than TuHURA Biosciences. MarketBeat recorded 5 mentions for Zevra Therapeutics and 2 mentions for TuHURA Biosciences. Zevra Therapeutics' average media sentiment score of 1.27 beat TuHURA Biosciences' score of 1.08 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TuHURA Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is ZVRA or HURA more profitable? Zevra Therapeutics has a net margin of 4.33% compared to TuHURA Biosciences' net margin of 0.00%. Zevra Therapeutics' return on equity of -112.40% beat TuHURA Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics4.33% -112.40% -37.67% TuHURA Biosciences N/A -248.79%-150.83% Which has preferable valuation & earnings, ZVRA or HURA? TuHURA Biosciences has lower revenue, but higher earnings than Zevra Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$23.61M17.34-$105.51M-$0.21-34.74TuHURA BiosciencesN/AN/A-$21.68MN/AN/A SummaryZevra Therapeutics beats TuHURA Biosciences on 10 of the 14 factors compared between the two stocks. Get TuHURA Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for HURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding HURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HURA vs. The Competition Export to ExcelMetricTuHURA BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$119.86M$3.10B$5.75B$10.27BDividend YieldN/A2.32%5.73%4.60%P/E RatioN/A21.4675.2326.34Price / SalesN/A246.37458.6889.55Price / CashN/A44.4425.8129.91Price / Book7.049.5913.246.27Net Income-$21.68M-$53.20M$3.29B$270.67M7 Day Performance-4.96%-0.02%0.69%2.71%1 Month Performance-21.73%3.82%4.50%5.87%1 Year PerformanceN/A8.98%73.37%25.85% TuHURA Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HURATuHURA Biosciences1.7447 of 5 stars$2.40-4.2%$12.67+428.9%N/A$119.86MN/A0.00N/AZVRAZevra Therapeutics3.0105 of 5 stars$8.33-6.9%$23.71+184.7%-1.3%$502.41M$23.61M-39.6720Analyst DowngradePRMEPrime Medicine3.4191 of 5 stars$3.89+4.6%$8.92+129.2%-0.5%$500.62M$4.96M-1.90234Gap UpBCYCBicycle Therapeutics3.1056 of 5 stars$7.00-2.2%$22.22+217.5%-73.8%$495.86M$35.28M-1.99240EOLSEvolus4.0715 of 5 stars$7.61-0.7%$21.25+179.2%-58.9%$495.49M$266.27M-7.77170Positive NewsREPLReplimune Group3.9786 of 5 stars$6.04-4.6%$6.50+7.6%-48.5%$494.09MN/A-1.86210CMPSCOMPASS Pathways3.2447 of 5 stars$4.98-3.1%$16.29+227.0%-28.3%$493.14MN/A-2.71120Positive NewsRGNXREGENXBIO4.5956 of 5 stars$9.48-2.4%$28.38+199.3%-28.3%$490.49M$83.33M-2.76370Positive NewsARCTArcturus Therapeutics3.0373 of 5 stars$17.84-0.1%$50.57+183.5%-16.5%$484.72M$109.80M-8.00180Positive NewsCMPXCompass Therapeutics2.384 of 5 stars$3.44flat$12.89+274.7%+116.4%$475.69M$850K-7.6420Positive NewsETONEton Pharmaceuticals2.1421 of 5 stars$17.78+0.6%$29.67+66.9%+242.7%$473.87M$39.01M-111.1320News CoveragePositive News Related Companies and Tools Related Companies ZVRA Competitors PRME Competitors BCYC Competitors EOLS Competitors REPL Competitors CMPS Competitors RGNX Competitors ARCT Competitors CMPX Competitors ETON Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:HURA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGENIUS Act: The Plot to Seize Your Cash?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TuHURA Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TuHURA Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HURA Stock Alerts